Template:Erysipelas antibiotics - Revision history

Danbot: Add pediatric dosing section

2026-03-20T13:01:16Z

Add pediatric dosing section

← Older revision		Revision as of 13:01, 20 March 2026
Line 7:		Line 7:
	*{{AntibioticDose\|disease=Erysipelas\|drug=Amoxicillin/Clavulanate\|dose=500mg PO BID x 10 days\|context=Treatment Failure}} (generally reserved for failure of first line therapy)		*{{AntibioticDose\|disease=Erysipelas\|drug=Amoxicillin/Clavulanate\|dose=500mg PO BID x 10 days\|context=Treatment Failure}} (generally reserved for failure of first line therapy)
	Bullous Erysipela or [[MRSA]] suspected: [[trimethoprim-sulfamethoxazole]], [[clindamycin]], [[doxycycline]], or [[minocycline]]		Bullous Erysipela or [[MRSA]] suspected: [[trimethoprim-sulfamethoxazole]], [[clindamycin]], [[doxycycline]], or [[minocycline]]

			====Pediatric====
			*{{AntibioticDose\|disease=Erysipelas\|drug=Penicillin G\|dose=<30kg: 300,000 U/day IM; >30kg: 600,000-1 million U/day IM\|context=Pediatric First Line\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Erysipelas\|drug=Cephalexin\|dose=25-50mg/kg/day PO divided q6-8h x 10 days (max 500mg/dose)\|context=Pediatric\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Erysipelas\|drug=Clindamycin\|dose=30mg/kg/day PO divided TID x 10 days (max 1.8g/day)\|context=Pediatric PCN Allergy\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Erysipelas\|drug=Ceftriaxone\|dose=50mg/kg IV daily (max 2g) x 10 days\|context=Pediatric Inpatient\|population=Pediatric}}

Danbot: Convert to AntibioticDose with disease=Erysipelas

2026-03-20T01:00:42Z

Convert to AntibioticDose with disease=Erysipelas

← Older revision		Revision as of 01:00, 20 March 2026
Line 1:		Line 1:
	''Coverage for [[S. pyogenes]]''		''Coverage for [[S. pyogenes]]''
	*[[Penicillin G]] 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR'''		*{{AntibioticDose\|disease=Erysipelas\|drug=Penicillin G\|dose=300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg\|context=First Line}} (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR'''
	*[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) '''OR'''		*{{AntibioticDose\|disease=Erysipelas\|drug=Clindamycin\|dose=450mg (5mg/kg) PO q8hrs x 10 days\|context=PCN Allergic}} (if PCN allergic) '''OR'''
	*[[Cephalexin]] 500mg (6.25mg/kg) PO q6hrs x 10 days '''OR'''		*{{AntibioticDose\|disease=Erysipelas\|drug=Cephalexin\|dose=500mg (6.25mg/kg) PO q6hrs x 10 days\|context=Alternative}} '''OR'''
	*[[Ceftriaxone]] 1g (50mg/kg) IV once daily x 10 days '''OR'''		*{{AntibioticDose\|disease=Erysipelas\|drug=Ceftriaxone\|dose=1g (50mg/kg) IV once daily x 10 days\|context=Inpatient}} '''OR'''
	*[[Levofloxacin]] 500mg PO/IV daily x 10 days '''OR'''		*{{AntibioticDose\|disease=Erysipelas\|drug=Levofloxacin\|dose=500mg PO/IV daily x 10 days\|context=Alternative}} '''OR'''
	*~~[[Augmentin]]~~ 500mg PO BID x 10 days (generally reserved for failure of first line therapy)		*{{AntibioticDose\|disease=Erysipelas\|drug=Amoxicillin/Clavulanate\|dose=500mg PO BID x 10 days\|context=Treatment Failure}} (generally reserved for failure of first line therapy)

	Bullous Erysipela or [[MRSA]] suspected: [[trimethoprim-sulfamethoxazole]], [[clindamycin]], [[doxycycline]], or [[minocycline]]		Bullous Erysipela or [[MRSA]] suspected: [[trimethoprim-sulfamethoxazole]], [[clindamycin]], [[doxycycline]], or [[minocycline]]

Rossdonaldson1 at 13:38, 23 November 2017

2017-11-23T13:38:18Z

← Older revision		Revision as of 13:38, 23 November 2017
Line 1:		Line 1:
	''Coverage for [[S. pyogenes]]''		''Coverage for [[S. pyogenes]]''

	*[[Penicillin G]] 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR'''		*[[Penicillin G]] 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR'''
	*[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) '''OR'''		*[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) '''OR'''
Line 7:		Line 6:
	*[[Levofloxacin]] 500mg PO/IV daily x 10 days '''OR'''		*[[Levofloxacin]] 500mg PO/IV daily x 10 days '''OR'''
	*[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy)		*[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy)

			Bullous Erysipela or [[MRSA]] suspected: [[trimethoprim-sulfamethoxazole]], [[clindamycin]], [[doxycycline]], or [[minocycline]]

Mholtz at 08:20, 22 August 2015

2015-08-22T08:20:18Z

← Older revision		Revision as of 08:20, 22 August 2015
Line 5:		Line 5:
	*[[Cephalexin]] 500mg (6.25mg/kg) PO q6hrs x 10 days '''OR'''		*[[Cephalexin]] 500mg (6.25mg/kg) PO q6hrs x 10 days '''OR'''
	*[[Ceftriaxone]] 1g (50mg/kg) IV once daily x 10 days '''OR'''		*[[Ceftriaxone]] 1g (50mg/kg) IV once daily x 10 days '''OR'''
			*[[Levofloxacin]] 500mg PO/IV daily x 10 days '''OR'''
	*[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy)		*[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy)

Mholtz at 08:14, 22 August 2015

2015-08-22T08:14:30Z

← Older revision		Revision as of 08:14, 22 August 2015
Line 1:		Line 1:
	''Coverage for [[S. pyogenes]]''		''Coverage for [[S. pyogenes]]''
	*[[Penicillin G]] (300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg) OR
	*[[~~Amoxicillin~~]] ~~500mg~~ PO q8hrs 10 days OR		*[[Penicillin G]] 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR'''
	*[[~~Clindamycin~~]] ~~450mg~~ (~~5mg~~/kg) PO ~~q8hrs~~ x 10 days OR		*[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) '''OR'''
	*[[Ceftriaxone]] 1g (50mg/kg) IV once daily x 10 days		*[[Cephalexin]] 500mg (6.25mg/kg) PO q6hrs x 10 days '''OR'''
	*[[~~Cephalexin~~]] 500mg (~~6.25mg/kg~~) ~~PO q6hrs~~		*[[Ceftriaxone]] 1g (50mg/kg) IV once daily x 10 days '''OR'''
			*[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy)

Yoshmd: Created page with "''Coverage for S. pyogenes'' Penicillin G (300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg) OR Amoxicillin 500mg PO q8hrs 10 days OR *[[Clindamycin]..."

2015-04-21T18:25:36Z

Created page with "''Coverage for S. pyogenes'' *Penicillin G (300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg) OR *Amoxicillin 500mg PO q8hrs 10 days OR *[[Clindamycin]..."

New page

''Coverage for [[S. pyogenes]]''
*[[Penicillin G]] (300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg) OR
*[[Amoxicillin]] 500mg PO q8hrs 10 days OR
*[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days OR
*[[Ceftriaxone]] 1g (50mg/kg) IV once daily x 10 days
*[[Cephalexin]] 500mg (6.25mg/kg) PO q6hrs